ATE218583T1 - Verbindungen mit aggregations-modulierenden wirkung auf das amyloid protein - Google Patents

Verbindungen mit aggregations-modulierenden wirkung auf das amyloid protein

Info

Publication number
ATE218583T1
ATE218583T1 AT96908805T AT96908805T ATE218583T1 AT E218583 T1 ATE218583 T1 AT E218583T1 AT 96908805 T AT96908805 T AT 96908805T AT 96908805 T AT96908805 T AT 96908805T AT E218583 T1 ATE218583 T1 AT E218583T1
Authority
AT
Austria
Prior art keywords
aggregation
compounds
natural
amyloid
peptides
Prior art date
Application number
AT96908805T
Other languages
English (en)
Inventor
Mark A Findeis
Howard Benjamin
Marc B Garnick
Malcolm L Gefter
Arvind Hundal
Laura Kasman
Gary Musso
Ethan R Signer
James Wakefield
Michael J Reed
Susan Molineaux
William Kubasek
Joseph Chin
Jung-Ja Lee
Michael Kelley
Original Assignee
Praecis Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27410601&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE218583(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/404,831 external-priority patent/US5817626A/en
Priority claimed from US08/475,579 external-priority patent/US5854215A/en
Application filed by Praecis Pharm Inc filed Critical Praecis Pharm Inc
Application granted granted Critical
Publication of ATE218583T1 publication Critical patent/ATE218583T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
AT96908805T 1995-03-14 1996-03-14 Verbindungen mit aggregations-modulierenden wirkung auf das amyloid protein ATE218583T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/404,831 US5817626A (en) 1995-03-14 1995-03-14 Modulators of beta-amyloid peptide aggregation
US08/475,579 US5854215A (en) 1995-03-14 1995-06-07 Modulators of β-amyloid peptide aggregation
US54899895A 1995-10-27 1995-10-27
PCT/US1996/003492 WO1996028471A1 (en) 1995-03-14 1996-03-14 Modulators of amyloid aggregation

Publications (1)

Publication Number Publication Date
ATE218583T1 true ATE218583T1 (de) 2002-06-15

Family

ID=27410601

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96908805T ATE218583T1 (de) 1995-03-14 1996-03-14 Verbindungen mit aggregations-modulierenden wirkung auf das amyloid protein

Country Status (8)

Country Link
US (5) US6319498B1 (de)
EP (1) EP0815134B1 (de)
JP (1) JPH11514333A (de)
AT (1) ATE218583T1 (de)
CA (1) CA2214247C (de)
DE (1) DE69621607T2 (de)
ES (1) ES2175083T3 (de)
WO (1) WO1996028471A1 (de)

Families Citing this family (205)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780587A (en) * 1990-08-24 1998-07-14 President And Fellows Of Harvard College Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
JPH11514333A (ja) * 1995-03-14 1999-12-07 プレーシス ファーマスーティカルズ インコーポレイテッド アミロイドの凝集の調節剤
US6303567B1 (en) * 1995-03-14 2001-10-16 Praecis Pharmaceuticals, Inc . Modulators of β-amyloid peptide aggregation comprising D-amino acids
US5948763A (en) * 1995-06-07 1999-09-07 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
US5985242A (en) * 1995-10-27 1999-11-16 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
US6277826B1 (en) 1996-08-27 2001-08-21 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
EP0866805A1 (de) 1995-12-12 1998-09-30 Karolinska Innovations AB Peptide, das die KLVFF Sequenz von beta-Amyloid bindet
DE69733655T2 (de) * 1996-08-27 2006-04-27 Praecis Pharmaceuticals, Inc., Cambridge beta-AMYLOID PEPTIDAGGREGATION REGULIERENDE PEPTIDE MIT D-AMINOSÄUREN
US6022859A (en) * 1996-11-15 2000-02-08 Wisconsin Alumni Research Foundation Inhibitors of β-amyloid toxicity
WO1998030229A1 (en) * 1997-01-10 1998-07-16 Massachusetts Institute Of Technology TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE BY β-AMYLOID PEPTIDES
US7045531B1 (en) 1997-03-11 2006-05-16 The General Hospital Corporation Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator
JP2001514661A (ja) * 1997-03-11 2001-09-11 ザ ジェネラル ホスピタル コーポレイション アルツハイマー病の処置における使用のための薬剤の同定
DE19725619A1 (de) * 1997-06-17 1998-12-24 Fraunhofer Ges Forschung Peptide als Agonisten und/oder Inhibitoren der Amyloidbildung und Zytotoxizität sowie der Verwendung bei Alzheimer'schen Krankheit, beim Typ II Diabetes mellitus und bei spongiformen Encephalopathien
US7078191B1 (en) 1997-08-01 2006-07-18 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Composition and method for the detection of diseases associated with amyloid-like fibril or protein aggregate formation
CA2301142A1 (en) * 1997-08-14 1999-02-25 The Regents Of The University Of California Fluorescent amyloid a.beta. peptides and uses thereof
US6703015B1 (en) * 1999-09-03 2004-03-09 Ramot At Tel-Aviv University Ltd. Filamentous bacteriophage displaying an β-amyloid epitope
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7799535B1 (en) * 1997-12-09 2010-09-21 Arch Development Corporation Methods for identifying factors that control the folding of amyloid proteins of diverse origin
WO1999041279A2 (en) * 1998-02-13 1999-08-19 Arch Development Corporation Methods and compositions comprising the use of blocked b-amyloid peptide
US6323218B1 (en) 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease
US6638711B1 (en) 1999-04-29 2003-10-28 The General Hospital Corporation Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation
US6211149B1 (en) 1998-08-03 2001-04-03 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors of formation of protease resistant prion protein
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US7122620B1 (en) * 1998-05-27 2006-10-17 Medical Research Services And Development Ltd. Haptotactic peptides
US7595199B1 (en) 1998-07-31 2009-09-29 Max-Planck-Gesellschaft zur Förderung der Wissenchaften e.V. Method of detecting amyloid-like fibrils or protein aggregates
NZ514414A (en) * 1999-03-04 2004-02-27 Praecis Pharm Inc Modulators of beta-amyloid peptide aggregation comprising D-amino acids
EP1870419A3 (de) * 1999-03-04 2008-01-02 Praecis Pharmaceuticals Incorporated Modulatoren der Beta-Amyloid-Peptid-Aggregation mit D-Aminosäuren
AU4529800A (en) * 1999-05-05 2000-11-21 Neurochem, Inc. Stereoselective antifibrillogenic peptides and peptidomimetics thereof
US7060670B1 (en) 1999-05-05 2006-06-13 Neurochem (International) Limited Stereoselective antifibrillogenic peptides and peptidomimetics thereof
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
EP1187920A2 (de) * 1999-06-09 2002-03-20 Arch Development Corporation Rekombinante prionänhliche gene, proteine, materialien und verfahren davon
AUPQ180499A0 (en) * 1999-07-23 1999-08-19 Biomolecular Research Institute Limited Beta-amyloid peptide inhibitors
AU6234700A (en) * 1999-07-27 2001-02-13 Abgenix, Inc. Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders
GB9917724D0 (en) 1999-07-28 1999-09-29 Medical Res Council Peptides
GB9917725D0 (en) 1999-07-28 1999-09-29 Medical Res Council Peptides
JP2003506411A (ja) * 1999-08-09 2003-02-18 トリペップ アクチ ボラゲット タンパク質重合阻害剤および使用方法
WO2001034631A2 (en) * 1999-11-05 2001-05-17 Axonyx, Inc. PEPTIDE ANALOGS AND MIMETICS SUITABLE FOR IN VIVO USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ABNORMAL PROTEIN FOLDING INTO AMYLOID, AMYLOID-LIKE DEPOSITS OR β-SHEET RICH PATHOLOGICAL PRECURSOR THEREOF
US6689753B1 (en) * 1999-11-05 2004-02-10 Axonyx, Inc. β sheet breaker peptide analogs that inhibit β pleated sheet formation in amyloid β-peptide
US20070135337A2 (en) * 1999-11-29 2007-06-14 Neurochem (International) Limited Vaccine for the Prevention and Treatment of Alzheimer's and Amyloid Related Diseases
US20020094335A1 (en) * 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
CA2398567A1 (en) * 2000-02-11 2001-08-16 Praecis Pharmaceuticals Incorporated Methods for enhancing the bioavailability of a drug
EE200200444A (et) * 2000-02-21 2003-12-15 Pharmexa A/S Meetod autoloogse beeta-amüloidvaigu in vivo mahasurumiseks, amüloidogeense polüpeptiidi analoog, seda kodeeriv nukleiinhappefragment ning kasutamineimmunogeense kompositsiooni valmistamiseks
KR100879810B1 (ko) * 2000-02-21 2009-01-22 하. 룬드벡 아크티에셀스카브 아밀로이드의 하향-조절을 위한 신규한 방법
US20070179197A1 (en) * 2000-05-01 2007-08-02 Accera, Inc. Compositions and methods for improving or preserving brain function
WO2001082928A1 (en) 2000-05-01 2001-11-08 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
AU2001268005A1 (en) * 2000-07-07 2002-01-21 Lars Lannfelt Prevention and treatment of alzheimer's disease
AU2007200047B2 (en) * 2000-07-07 2009-11-26 Bioarctic Neuroscience Ab Prevention and treatment of Alzheimer's disease
US6472436B1 (en) 2000-07-17 2002-10-29 The Salk Institute For Biological Studies Methods for protecting cells from amyloid toxicity and for inhibiting amyloid protein production
US20030044413A1 (en) * 2000-08-15 2003-03-06 Regents Of The University Of Minnesota Methods of limiting apoptosis of cells
WO2002036614A2 (en) * 2000-11-01 2002-05-10 Insight Biotechnology Limited Peptides for use in the treatment of alzheimer's disease
GB0028710D0 (en) * 2000-11-24 2001-01-10 Isis Innovation Mixed fibrils
PT1346041E (pt) * 2000-11-27 2007-06-05 Praecis Pharm Inc Agentes terapêuticos e métodos para a sua utilização no tratamento de uma doença amiloidogénica.
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
DE10101430B4 (de) * 2001-01-13 2008-10-02 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Lösliche cyclische Analoga zur Modulation der Amyloidogenese
US7320793B2 (en) * 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
AU2002254328A1 (en) * 2001-03-20 2002-10-03 University Of Chicago Inhibitors and disassemblers of fibrillogenesis
JP2002346015A (ja) * 2001-05-28 2002-12-03 Hiroaki Yoshiike スイング診断装置
AU2002320045B2 (en) 2001-05-31 2008-05-08 Adlyfe, Inc. Misfolded protein sensor method
US7179784B2 (en) * 2001-07-10 2007-02-20 Massachusetts Institute Of Technology Surfactant peptide nanostructures, and uses thereof
MY144532A (en) * 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
US6593455B2 (en) * 2001-08-24 2003-07-15 Tripep Ab Tripeptide amides that block viral infectivity and methods of use thereof
US20030082191A1 (en) * 2001-08-29 2003-05-01 Poduslo Joseph F. Treatment for central nervous system disorders
US20030170810A1 (en) * 2001-09-18 2003-09-11 Masoud Vedadi Methods and apparatuses for purification
WO2003024995A1 (en) * 2001-09-19 2003-03-27 Tripep Ab Molecules that block viral infectivity and methods of use thereof
US20040038861A1 (en) * 2001-11-26 2004-02-26 Cooper Garth J. S. Methods and compositions for normalizing lipid levels in mammalian tissues
AU2002366355A1 (en) * 2001-12-17 2003-06-30 New York State Office Of Mental Health SEQUESTRATION OF ABeta IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES
WO2003059387A2 (en) * 2001-12-21 2003-07-24 Ilex Oncology, Inc. Combination comprising anti-cd52 antibodies and other therapeutic agents for treatment for multiple sclerosis
CA2473102A1 (en) * 2002-01-29 2003-07-29 Protemix Corporation Limited Suppression of cytotoxic protein conformers
US20040052928A1 (en) 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
AU2004203461B2 (en) * 2002-01-31 2009-09-03 Tel Aviv University Future Technology Development L.P. Peptides Antibodies Directed Thereagainst and Methods Using Same for Diagnosing and Treating Amyloid-Associated Diseases
EP1820806A1 (de) * 2006-02-16 2007-08-22 Crossbeta Biosciences B.V. Affinitätsbereiche
TW200416037A (en) * 2002-02-20 2004-09-01 Kanegafuchi Chemical Ind Process for producing hydrophobic glycyrrhiza extract with high qualities
US20050079526A1 (en) * 2002-02-20 2005-04-14 Affinium Pharmaceuticals, Inc. Methods and apparatuses for characterizing refolding and aggregation of biological molecules
CA2477021A1 (en) * 2002-02-20 2003-08-28 Affinium Pharmaceuticals, Inc. Methods and apparatuses for characterizing stability of biological molecules
US20050148650A1 (en) 2002-03-01 2005-07-07 Shigenori Ohkawa Antidepressant
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
AU2003226007A1 (en) * 2002-03-22 2003-10-13 Emory University Self-assembling-peptide-based structures and processes for controlling the self-assembly of such structures
WO2003087834A2 (en) * 2002-04-08 2003-10-23 Affinium Pharmaceuticals, Inc. High throughput analysis of recombinant proteins in multi-well plates
US6846640B2 (en) * 2002-04-30 2005-01-25 Pharmacia & Upjohn Company Time-resolved fluorescence assay for the detection of multimeric forms of A-beta 1-40
DE10221052A1 (de) * 2002-05-10 2003-12-04 Transmit Technologietransfer Wirkstoffe zu Therapie, Diagnostik und Prophylaxe von Erkrankungen, bei denen abnorme Proteinstrukturen auftreten
US20070003552A1 (en) * 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
EP1380290A1 (de) * 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-Beta-Strukturweg und seine therapeutische Relevanz
CA2487528A1 (en) * 2002-07-24 2004-02-12 Innogenetics N.V. Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation
US20040121445A1 (en) * 2002-07-31 2004-06-24 Fabien Marino Cell cultures
US7345022B2 (en) 2002-09-19 2008-03-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Anti-fibril peptides
CA2515679A1 (en) * 2003-02-21 2004-09-02 Tripep Ab Glycinamide derivative for inhibiting hiv replication
US20050096319A1 (en) * 2003-02-21 2005-05-05 Balzarini Jan M.R. Identification of compounds that inhibit replication of human immunodeficiency virus
CN1756554A (zh) * 2003-03-06 2006-04-05 艾克塞拉公司 新的化学实体和它们用于治疗代谢障碍的方法
WO2004094463A2 (en) * 2003-04-18 2004-11-04 University Of Florida Research Foundation, Inc. Peptide inhibitors of autophosphorylation protein kinases
US20070293422A1 (en) * 2003-04-30 2007-12-20 Applied Research Systems Ars Holding N.V. Beta-Amyloid Inhibitors and Use Thereof
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
JP4888876B2 (ja) * 2003-06-13 2012-02-29 田平 武 アルツハイマー病の治療のための組換えアデノ随伴ウィルスベクター
CA2530927A1 (en) 2003-06-30 2005-01-06 Tel Aviv University Future Technology Development L.P. Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
CA2540407A1 (en) 2003-09-25 2005-03-31 Tel Aviv University Future Technology Development L.P. Compositions and methods using same for treating amyloid-associated diseases
WO2005059100A2 (en) * 2003-12-12 2005-06-30 New York University Methods and compositions relating to cystatin c
AU2004311796A1 (en) * 2003-12-31 2005-07-21 Centocor, Inc. Novel recombinant proteins with N-terminal free thiol
PL1755661T3 (pl) 2004-05-12 2014-10-31 Brigham & Womens Hospital Inc Gelsolina do stosowania w leczeniu infekcji
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
JP5048486B2 (ja) * 2004-07-16 2012-10-17 トラスティーズ オブ タフツ カレッジ アポリポタンパク質ａ１の模倣物とその使用
US20060057671A1 (en) * 2004-09-10 2006-03-16 Orser Cindy S Immobilized probes and methods of detecting conformationally altered prion proteins
US7161443B2 (en) * 2004-09-30 2007-01-09 Broadcom Corporation Temperature compensated crystal oscillator
US7625560B2 (en) 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
JP2008523815A (ja) 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミテッド 認知の改善における使用のためのヒト化アミロイドβ抗体
US20090202980A1 (en) * 2005-03-21 2009-08-13 Crossbeta Biosciences B.V. Cross-Beta Structure Comprising Amyloid Binding Proteins and Methods for Detection of the Cross-Beta Structure, for Modulating Cross-Beta Structures Fibril Formation and for Modulating Cross-Beta Structure-Mediated Toxicity and Method for Interfering With Blood Coagulation
WO2006110621A2 (en) * 2005-04-11 2006-10-19 Cornell Research Foundation, Inc. Multiplexed biomarkers for monitoring the alzheimer's disease state of a subject
US20060252775A1 (en) * 2005-05-03 2006-11-09 Henderson Samuel T Methods for reducing levels of disease associated proteins
EP2468273A3 (de) * 2005-06-20 2012-07-11 Accera, Inc. Verfahren zur Reduzierung von oxidativer Schädigung und zur Verbesserung der mitochondrialen Effizienz
US8114832B2 (en) * 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
AU2006267176A1 (en) * 2005-07-13 2007-01-18 Crossbeta Biosciences B.V. Cross-beta structure binding compounds
EP1906995A2 (de) * 2005-07-13 2008-04-09 Crossbeta Biosciences B.V. Adjuvation durch kreuzstruktur
US7812025B2 (en) 2005-08-12 2010-10-12 Takeda Pharmaceutical Company Limited Brain/neuronal cell-protecting agent and therapeutic agent for sleep disorder
US20100130416A1 (en) * 2005-11-10 2010-05-27 Archer Pharmaceuticals, Inc. Modulation of angiogenesis by a-beta peptide fragments
WO2007059000A2 (en) * 2005-11-10 2007-05-24 Roskamp Research, Llc Modulation of angiogenesis by a-beta peptide fragments
KR20180058863A (ko) 2005-11-30 2018-06-01 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
CA2632822C (en) 2005-12-12 2018-08-28 Ruth Greferath A beta 1-42 specific monoclonal antibodies with therapeutic properties
US8669418B2 (en) 2005-12-22 2014-03-11 Vib Vzw Means and methods for mediating protein interference
EP2345417A1 (de) * 2005-12-22 2011-07-20 Vib Vzw Mittel und Verfahren zur Interferenz mit Proteinen
JP5888832B2 (ja) * 2005-12-22 2016-03-22 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー（ヴェーイーベー・ヴェーゼットウェー）Ｖｌａａｍｓ Ｉｎｔｅｒｕｎｉｖｅｒｓｉｔａｉｒ Ｉｎｓｔｉｔｕｕｔ Ｖｏｏｒ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅ Ｖｚｗ（Ｖｉｂ Ｖｚｗ） タンパク質干渉を媒介する手段および方法
PL2001496T3 (pl) 2006-03-15 2017-10-31 Brigham & Womens Hospital Inc Zastosowanie gelsoliny do diagnozowania i leczenia chorób zapalnych
PL2004688T5 (pl) * 2006-03-23 2014-09-30 Bioarctic Neuroscience Ab Ulepszone przeciwciała wobec protofibryli oraz ich zastosowania
PT2001293T (pt) 2006-04-03 2018-11-28 Accera Inc Utilização de compostos cetogénicos para tratamento de comprometimento da memória associado à idade
TWI334784B (en) * 2006-04-14 2010-12-21 Buck Inst For Age Res Compositions and methods for suppression of amyloid plaque formation associated with neurodegenerative disorders
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
DE112007001030T5 (de) * 2006-04-28 2009-02-26 Kagoshima University Amyloid-ß-Fibrillogenese-inhibierendes Peptid
US8673579B2 (en) * 2006-07-28 2014-03-18 Adlyfe, Inc. Peptide probes for diagnostics and therapeutics
US8188046B2 (en) * 2006-10-16 2012-05-29 University Of South Florida Amyloid beta peptides and methods of use
AU2008215948A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of AD and related conditions
US7618944B2 (en) * 2007-03-01 2009-11-17 Intezyne Technologies, Inc. Encapsulated amyloid-beta peptides
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
CN101795703B (zh) * 2007-06-27 2015-05-06 里兰斯坦福初级大学理事会 肽酪氨酸酶抑制剂及其应用
KR101561709B1 (ko) * 2007-06-27 2015-10-22 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 올리고펩티드 티로시나제 억제제 및 그의 용도
WO2009005783A1 (en) * 2007-06-28 2009-01-08 Blanchette Rockefeller Neurosciences Institute Peptides, compositions and methods for reducing beta-amyloid-mediated apoptosis
ES2498040T3 (es) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
ES2608286T3 (es) 2007-07-31 2017-04-07 Accera, Inc. Uso de ensayos genómicos y compuestos cetogénicos para tratamiento de una función cognitiva reducida
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
WO2009059239A2 (en) * 2007-11-02 2009-05-07 Mayo Foundation For Medical Education And Research REDUCING Aβ42 LEVELS AND Aβ AGGREGATION
EP2058001A1 (de) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Steigerung der Immunogenizität von Antigenen
EP2058000A1 (de) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Zur Aktivierung von T-Zellen fähige immunogene Zusammensetzung
DK2708603T3 (en) 2008-01-25 2017-08-14 Massachusetts Gen Hospital Diagnostic and therapeutic applications of gelsolin in renal failure
US8852874B2 (en) * 2008-02-29 2014-10-07 Baxter International Inc. Anti-amyloid β activity of intravenous immunoglobulin (IVIG) in vitro
KR101734152B1 (ko) * 2008-07-03 2017-05-11 액세라인크 신경계 장애의 치료를 위한 아세토아세테이트의 모노글리세리드 및 유도체
US8105809B2 (en) * 2008-07-03 2012-01-31 Accera, Inc. Enzymatic synthesis of acetoacetate esters and derivatives
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
WO2010091253A1 (en) 2009-02-06 2010-08-12 Women & Infants' Hospital Of Rhode Island Compositions, formulations and methods of treating preeclampsia-type disorders of pregnancy
US8288390B2 (en) 2009-03-10 2012-10-16 Takeda Pharmaceutical Company Limited Benzofuran derivatives
US9023767B2 (en) * 2009-05-07 2015-05-05 Memorial Sloan-Kettering Cancer Center γ-Secretase substrates and methods of use
JP5554528B2 (ja) * 2009-09-08 2014-07-23 国立大学法人 岡山大学 新規アミロイドβ凝集体結合性ペプチドおよび新規アミロイドβ凝集体結合性ペプチドを用いたアミロイド病の検査方法
CN103502466A (zh) 2010-09-07 2014-01-08 斯隆－凯特林纪念癌症中心 用于γ-分泌酶测定的方法和组合物
AU2011313150A1 (en) 2010-10-07 2013-04-18 Takeda Pharmaceutical Company Limited 1,4-oxazepane derivatives
AU2011330768A1 (en) 2010-11-15 2013-05-30 Merz Pharma Gmbh & Co. Kgaa Dipeptide analogs for treating conditions associated with amyloid fibril formation
WO2013021353A1 (en) 2011-08-11 2013-02-14 Bar-Ilan University Surface modified proteinaceous spherical particles and uses thereof
HUE043171T2 (hu) 2011-10-07 2019-08-28 Takeda Pharmaceuticals Co Neurodegeneratív betegségek kezelésére hasznos 1-arilkarbonil-4-oxi-piperidinvegyületek
DE102012102998B4 (de) * 2012-04-05 2013-12-05 Forschungszentrum Jülich GmbH Polymere, enthaltend multivalente Amyloid-Beta-bindende D-Peptide und deren Verwendung
EP2834644B1 (de) 2012-04-05 2019-08-21 Forschungszentrum Jülich GmbH Polymere, enthaltend multivalente amyloid-beta-bindende d-peptide und deren verwendung
CN104380110A (zh) 2012-04-05 2015-02-25 于利希研究中心有限公司 处理血液、血液产品和器官的方法
US20150087591A1 (en) * 2012-04-26 2015-03-26 Amylex Pharmaceuticals, Inc. Novel Composition for Extracorporeal Reduction of Beta-Amyloids and Process for Producing Thereof
EP2927229B1 (de) 2012-10-16 2018-09-05 Takeda Pharmaceutical Company Limited Zur vorbeugung oder behandlung von neurodegenerativen erkrankungen oder epilepsie geeignete benzol-kondensierte fünfgliedrige stickstoff enthaltende heteroaromatische verbindungen
UA115156C2 (uk) 2012-12-11 2017-09-25 Такеда Фармасьютікал Компані Лімітед Гетероциклічна сполука
JP5804463B2 (ja) 2012-12-27 2015-11-04 国立研究開発法人科学技術振興機構 環状ペプチド及びこれを含有する医薬
US20140280367A1 (en) * 2013-03-14 2014-09-18 Sap Ag Silo-aware databases
JP6272833B2 (ja) 2013-04-04 2018-01-31 武田薬品工業株式会社 複素環化合物
EP2982666B1 (de) 2013-04-04 2019-08-07 Takeda Pharmaceutical Company Limited Heterocyclische verbindung
DE102014003262A1 (de) 2014-03-12 2015-09-17 Forschungszentrum Jülich GmbH Amyloid-Beta-bindende Peptide und deren Verwendung für die Therapie und die Diagnose der Alzheimerschen Demenz
WO2015042326A2 (en) * 2013-09-18 2015-03-26 University Of Notre Dame Du Lac Methods for detection and treatment of neurodegenerative diseases
EP3049099B1 (de) 2013-09-26 2020-06-17 Forschungszentrum Jülich GmbH Amyloid-beta-bindende peptide und deren verwendung für die therapie und die diagnose der alzheimerschen demenz
EP3152198B1 (de) 2014-06-09 2019-02-27 Takeda Pharmaceutical Company Limited Radioaktiv markierte verbindungen
SMT202100263T1 (it) 2014-07-10 2021-07-12 Eisai R&D Man Co Ltd Anticorpi leganti protofibrille a-beta migliorati
GB201414038D0 (en) * 2014-08-07 2014-09-24 Univ Sussex The Alzheimer's disease
CN108350052A (zh) 2015-11-09 2018-07-31 英属哥伦比亚大学 淀粉样蛋白β中间区域中的表位及其构象选择性抗体
KR20180094876A (ko) 2015-11-09 2018-08-24 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타 에피토프 및 이에 대한 항체
HRP20220127T1 (hr) 2016-02-04 2022-04-15 Takeda Pharmaceutical Company Limited Supstituirani spoj piperidina i njegova uporaba
US12071472B2 (en) 2016-07-18 2024-08-27 The University Of British Columbia Methods of reducing toxicity induced by Amyloid beta (A-beta) oligomers using antibodies specific to A-beta oligomers
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
WO2018164191A1 (ja) 2017-03-08 2018-09-13 武田薬品工業株式会社 置換ピロリジン化合物およびその用途
CA3058848A1 (en) 2017-05-09 2018-11-15 Vib Vzw Means and methods for treating bacterial infections
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
JP7114594B2 (ja) 2017-07-28 2022-08-08 武田薬品工業株式会社 複素環化合物
EP3663281B1 (de) 2017-08-03 2022-12-28 Takeda Pharmaceutical Company Limited Heterocyclische verbindung und anwendung davon
WO2019189945A1 (en) 2018-03-28 2019-10-03 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US12077522B2 (en) 2018-06-29 2024-09-03 Takeda Pharmaceutical Company Limited Heterocyclic compound and application thereof
WO2020153414A1 (ja) 2019-01-24 2020-07-30 武田薬品工業株式会社 複素環化合物及びその用途
TW202523658A (zh) 2019-05-24 2025-06-16 美商賽吉醫療公司 化合物、組合物及使用方法
KR20220062361A (ko) 2019-09-13 2022-05-16 다케다 야쿠힌 고교 가부시키가이샤 과도한 졸림의 치료를 위한 오렉신 2 수용체 효능제의 용도
CA3154321A1 (en) 2019-09-13 2021-03-18 Takeda Pharmaceutical Company Limited Tak-925 for use in treating narcolepsy
JP2021050161A (ja) 2019-09-25 2021-04-01 武田薬品工業株式会社 複素環化合物及びその用途
CA3163200A1 (en) 2019-11-27 2021-06-03 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2022115620A1 (en) 2020-11-25 2022-06-02 Sage Therapeutics, Inc. 4-fluoro-(4-(4-benzyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone derivatives and similar compounds as cyp46a1 inhibitors for the treatment of neurodegenerative disorders
AR125073A1 (es) 2021-03-12 2023-06-07 Takeda Pharmaceuticals Co Uso de un agonista del receptor de orexina 2 para el tratamiento de una enfermedad o trastorno mediados por orexina
US20240165092A1 (en) 2021-04-02 2024-05-23 Takeda Pharmaceutical Limited Company Use of an orexin 2 receptor agonist for post operation recovery
EP4435096A4 (de) 2021-11-17 2025-11-26 Takeda Pharmaceuticals Co Zellherstellungsverfahren

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4119493A (en) * 1975-10-23 1978-10-10 (Zaidanhojin) Sagami Chemical Research Center Process for producing a peptide
US3937815A (en) * 1975-12-05 1976-02-10 SPA--Societa Prodotti Antibiotici S.p.A. Lysozyme derivatives
US4652627A (en) * 1985-08-16 1987-03-24 Kempe Tomas G Calcitonin analogs with C-terminal D-amino acid substituents
US5010174A (en) * 1987-07-08 1991-04-23 Mitsubishi Petrochemical Co., Ltd. Novel calcitonin derivative and salt thereof
US5284664A (en) 1988-08-04 1994-02-08 Kremers-Urban Company Method of treating the symptoms of Alzheimer's disease
JPH0459795A (ja) * 1990-06-26 1992-02-26 Sanwa Kagaku Kenkyusho Co Ltd カルシトニン様活性を有するポリペプチド誘導体及びその用途
US5338663A (en) 1990-08-24 1994-08-16 President And Fellows Of Harvard College Method of identifying inhibitors of β-protein esterase activity
US5434050A (en) 1991-08-13 1995-07-18 Regents Of The University Of Minnesota Labelled β-amyloid peptide and methods of screening for Alzheimer's disease
US5710244A (en) * 1992-12-31 1998-01-20 Labroo; Virender M. Derivatized calcitonins
US6120768A (en) * 1993-05-17 2000-09-19 Immunomedics, Inc. Dota-biotin derivatives
AU7043894A (en) * 1993-05-28 1994-12-20 Miriam Hospital, The Composition and method for (in vivo) imaging of amyloid deposits
CA2125467C (en) * 1993-07-06 2001-02-06 Heinz Dobeli Process for producing hydrophobic polypeptides, proteins or peptides
WO1995005604A2 (en) * 1993-08-13 1995-02-23 Molecular Geriatrics Corporation Methods for the diagnosis of alzheimer's disease
GB9317120D0 (en) 1993-08-17 1993-09-29 Royal Postgrad Med School Human serum amyloid p component
US5652334A (en) * 1993-09-08 1997-07-29 City Of Hope Method for design of substances that enhance memory and improve the quality of life
US5470951A (en) * 1993-09-29 1995-11-28 City Of Hope Peptides for antagonizing the effects of amyloid βprotein
US5744368A (en) * 1993-11-04 1998-04-28 Research Foundation Of State University Of New York Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR)
JPH07149668A (ja) 1993-11-30 1995-06-13 Kanegafuchi Chem Ind Co Ltd アミロイド沈着検出用物質
JPH09511492A (ja) 1994-02-03 1997-11-18 ザ ピコワー インスティテュート フォア メディカル リサーチ アミロイドーシスの前進性グリコシル化終末産物仲介モジュレーション用組成物及び方法
US5854215A (en) * 1995-03-14 1998-12-29 Praecis Pharmaceuticals Incorporated Modulators of β-amyloid peptide aggregation
JPH11514333A (ja) * 1995-03-14 1999-12-07 プレーシス ファーマスーティカルズ インコーポレイテッド アミロイドの凝集の調節剤
US5817626A (en) * 1995-03-14 1998-10-06 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation
US5698672A (en) * 1995-04-04 1997-12-16 Zymogenetics, Inc. Synthetic calcitonin mimetics
US5985242A (en) * 1995-10-27 1999-11-16 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids

Also Published As

Publication number Publication date
EP0815134B1 (de) 2002-06-05
US20020098173A1 (en) 2002-07-25
EP0815134A1 (de) 1998-01-07
DE69621607D1 (de) 2002-07-11
US20040005307A1 (en) 2004-01-08
CA2214247C (en) 2004-02-10
WO1996028471A1 (en) 1996-09-19
US20110009343A1 (en) 2011-01-13
JPH11514333A (ja) 1999-12-07
ES2175083T3 (es) 2002-11-16
US7658917B2 (en) 2010-02-09
US5854204A (en) 1998-12-29
US6319498B1 (en) 2001-11-20
DE69621607T2 (de) 2003-01-02
CA2214247A1 (en) 1996-09-19

Similar Documents

Publication Publication Date Title
ATE218583T1 (de) Verbindungen mit aggregations-modulierenden wirkung auf das amyloid protein
EA199900294A1 (ru) Сульфонамиды и их производные, модулирующие активность эндотелина
EA199700208A1 (ru) Тиенил-, фурил-, пирролил- и дифенилсульфонамиды и их производные, модулирующие активность эндотелина
ATE70718T1 (de) Pharmakadepotpraeparat.
FI914129A0 (fi) Nukleotidsekvens som kodar foer protein av den yttre membranen av neisseria meningitidis och an- anvaendning av naemnda protein i vaccin.
ES2123134T3 (es) Peptidos biologicamente activos de dominios funcionales de la proteina bactericida aumentadora de la permeabilidad y usos de los mismos.
DE69820108D1 (de) Doppelkapsel zur verabreichung von arzneimitteln für vielfache therapien
DE69738930D1 (de) Methoden zur modulation der melaninsynthese
NO20092874L (no) Forhindring og behandling av amyloidogen sykdom
ATE306931T1 (de) Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer
DE69410630D1 (de) Vorrichtung zur frühembryonalen in ovo injektion
ATE173880T1 (de) Biozide zusammensetzungen
DE69814394D1 (de) Verwendung von levobupivacain
DK1161449T3 (da) Modulatorer af beta-amyloidpeptidaggregering, der omfatter d-aminosyrer
DE69526216D1 (de) Antifungaleverfahren und mitteln
ATE280777T1 (de) Bradykinin-antagonist peptide mit n- substituierten glycinen
DE69836582D1 (de) Kurze peptide die die aktivität serine/threonine kinasen modulieren
FI940375A0 (fi) Peptidit, joilla on elimiä suojaavaa vaikutusta, menetelmä niiden valmistamiseksi ja niiden käyttö terapiassa
DE69127334D1 (de) Verabreichung von Mitteln
ATE82127T1 (de) N-acetylglucosamin-zubereitungen zur buccalen anwendung.
HUP9900506A2 (hu) Protrombinszármazékok
CA2200069A1 (en) Anti-Fungal Peptides
MX9706588A (es) Metodo para estimular una respuesta inmune.
PT101444A (pt) Associacao sinergizante com efeito antagonista dos receptores nk1 e nk2, uso de produtos com actividade antagonista dos receptores nk1 e nk2 na sua preparacao e composicao farmaceutica contendo a referida associacao
ES2087337T3 (es) Composiciones de implantes que contienen una proteina, peptido o polipeptido biologicamente activos.